Search

Your search keyword '"Kleinschmidt, Rolf"' showing total 16 results
Start Over Author "Kleinschmidt, Rolf"
16 results on '"Kleinschmidt, Rolf"'

1. High-dose chemotherapy with autologous peripheral blood stem cell support for recurrent primary AFP-producing intracranial germinoma

Author

Ziske, Carsten, Mezger, Jörg, Jiménez, Carlos, Kleinschmidt, Rolf, Pels, Hendrik, Schlegel, Uwe, and Schmidt-Wolf, Ingo G.H.

Subjects
Medicine
Abstract

We report of a 34-year old man with second intracranial relapse of a suprasellar germinoma. Despite of extensive pretreatment with radiation and conventional chemotherapy relapse occurred and was treated with sequential high-dose chemotherapy followed by transfusion of autologous peripheral stem cells. The high-dose chemotherapy course was complicated by refractory derailment of pineal gland insufficiency. The patient achieved a complete remission after high dose chemotherapy which lasted for 13 months. Subsequently, he developed a third relapse and died.

Published
2003

9. Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Author

Glasmacher, Axel, primary, Moehler, Thomas, additional, Goldschmidt, Hartmut, additional, Geer, Thomas, additional, Kleinschmidt, Rolf, additional, Gaska, Tobias, additional, Uwe, Janssens, additional, Schubert, Jorg, additional, Bruck, Patrick, additional, Clemens, Michael R., additional, Bair, Wolfgang, additional, Seipelt, Gernot, additional, Schleuning, Michael, additional, Hahn-Ast, Corinna, additional, Herz, Susanne, additional, von Lilienfeld-Toal, Marie, additional, Naumann, Ralf, additional, Gorschluter, Marcus, additional, and Schmidt-Wolf, Ingo G.H., additional

Published
2007
Full Text
View/download PDF

12. Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Author

Schmidt-Wolf, Ingo G.H., primary, Moehler, Thomas, additional, Goldschmidt, Hartmut, additional, Geer, Thomas, additional, Kleinschmidt, Rolf, additional, Gaska, Tobias, additional, Janssens, Uwe, additional, Schubert, Joerg, additional, Brueck, Patrick, additional, Clemens, Michael R., additional, Bair, Wolfgang, additional, Seipelt, Gernot, additional, Schleuning, Michael, additional, Hahn-Ast, Corinna, additional, Herz, Susanne, additional, von Lilienfeld-Toal, Marie, additional, Naumann, Ralph, additional, Gorschlueter, Marcus, additional, and Glasmacher, Axel, additional

Published
2006
Full Text
View/download PDF

15. Vindesine and etoposide: A practical and well-tolerated therapy for elderly patients or patients in reduced clinical condition with extensive-stage small-cell lung cancer (SCLC).

Author

Bonn O, Schmidt-Wolf G, Risse F, Glasmacher A, Kleinschmidt R, and Schmidt-Wolf IG

Subjects
Adult, Aged, Aged, 80 and over, Drug Therapy, Combination, Etoposide adverse effects, Female, Humans, Male, Middle Aged, Neoplasm Staging, Survival Rate, Vindesine adverse effects, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell pathology, Etoposide therapeutic use, Vindesine therapeutic use
Abstract

Background: Small-cell lung cancer is a disease affecting mostly elderly persons. Therefore, many patients show marked comorbidity and intensive chemotherapy is not possible in such patients. As the disease is most often in the 'extensive' stage at diagnosis, the therapy option is only palliative., Materials/methods: [corrected] We used a combination therapy with vindesine and etoposide in treating 41 patients (median age: 63 years) over 155 cycles of chemotherapy., Results: This treatment resulted in a response rate of 43.9% and a median survival time of 9.3 months and thus equals established schemes in its effectiveness. However, its rate of adverse effects (hematoxicity, gastrointestinal toxicity, neuropathy) is smaller than those of the established therapy schemes ACO, EPICO, or carboplatine/etoposide., Conclusions: Therapy of advanced SCLC with vindesine and etoposide can be applied in an ambulant setting and offers an improved quality of life with equivalent therapeutic effectivity. Therefore it is especially suitable for patients of older age and fragile condition due to comorbidity.

Published
2005

16. High-dose chemotherapy with autologous peripheral blood stem cell support for recurrent primary AFP-producing intracranial germinoma.

Author

Ziske C, Mezger J, Jiménez C, Kleinschmidt R, Pels H, Schlegel U, and Schmidt-Wolf IG

Abstract

We report of a 34-year old man with second intracranial relapse of a suprasellar germinoma. Despite of extensive pretreatment with radiation and conventional chemotherapy relapse occurred and was treated with sequential high-dose chemotherapy followed by transfusion of autologous peripheral stem cells. The high-dose chemotherapy course was complicated by refractory derailment of pineal gland insufficiency. The patient achieved a complete remission after high dose chemotherapy which lasted for 13 months. Subsequently, he developed a third relapse and died.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results